10-Q quarterly report · filed Oct 28, 2026

Bausch & Lomb Corp (BLCO) Q3 2026 10-Q Quarterly Report

Short answer

Bausch & Lomb Corp (BLCO) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.4B (up 7.3% year over year) with net income of $32M.

Q3 2026 key financials · XBRL

Revenue
$1.4B
+7.3% YoY · −1.4% QoQ
Net income
$32M
+214.3% YoY · +328.6% QoQ
Operating margin
11.3%
EPS (diluted)
$0.09
+228.6% YoY · +325.0% QoQ

Source: XBRL data from the Bausch & Lomb Corp (BLCO) Q3 2026 10-Q on SEC EDGAR. USD.

Bausch & Lomb Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $1,375M, up 7% YoY from $1,281M, driven by volume, pricing and acquisitions
  • Cost of goods sold margin 35.4% vs 39.9% YoY, supporting operating income of $155M vs $95M
  • Pharmaceuticals strongest growth: revenue $367M, up 11%; Vision Care largest segment at $774M
  • Operating cash flow $418M for nine months vs $147M YoY; investing cash use $290M, including $35M MIEBO milestone payment
  • Near-term headwinds: evolving tariffs, FDA Tampa warning letter, geopolitical conflicts and healthcare pricing pressure.calc

Risk Factors

  • Leadership transition risk: Thomas Appio became interim CEO October 12, 2026, following Brent Saunders’ departure
  • Governance conflict risk: Appio’s concurrent Bausch Health CEO role may divide management attention
  • Strategic execution risk: New chairman and interim CEO may change business strategy, creating stakeholder uncertainty
  • Market risk: Leadership disruption could reduce the market value of common shares

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.